We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Novel Method for Detecting Lung Cancer

By LabMedica International staff writers
Posted on 10 Oct 2011
A highly sensitive technology can detect lung cancer by identifying a specific small ribonucleic acid (microRNA) in the bloodstream, according to a new study.

Researchers at the University of Missouri (MU; Columbia, USA) used a nanopore sensor based on the α-haemolysin protein to detect selectively microRNAs at the single molecular level in plasma samples from lung cancer patients, without the need for labels or amplification of the microRNA. More...
When the target microRNA interacts with the functionalized lumen of the nanopore channel, it blocks the ion pathway in a characteristic way. The resulting conductance changes allow for the identification and quantification of the targeted single molecules in the mixture.

The nanopore sensor, which uses a programmable oligonucleotide probe to generate the target-specific signature signal, can quantify sub-picomolar levels of microRNAs, and can even distinguish single-nucleotide differences between specific microRNA family members. The nanopore sensors themselves can be assembled through genetic engineering using protein ion channels, and can alternatively be artificially fabricated on solid substrates using fashion nanotechnology. The study describing the technology was published in the October 2, 2011, issue of Nature Nanotechnology.

“While there are many research labs that focus on nanopore applications, this is the first time that nanopore technology has been used to detect lung cancer,” said corresponding author Li-Qun Gu, PhD, an associate professor of biological engineering. “This technology could possibly be used in the future to detect other cancer types, as well as other types of diseases with specific DNA or RNA in the blood.”

Related Links:

University of Missouri





Gold Member
Blood Gas Analyzer
Stat Profile pHOx
Collection and Transport System
PurSafe Plus®
New
Gold Member
Automatic Hematology Analyzer
DH-800 Series
Capillary Blood Collection Tube
IMPROMINI M3
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Hematology

view channel
Image: New evidence shows viscoelastic testing can improve assessment of blood clotting during postpartum hemorrhage (Photo courtesy of 123RF)

Viscoelastic Testing Could Improve Treatment of Maternal Hemorrhage

Postpartum hemorrhage, severe bleeding after childbirth, remains one of the leading causes of maternal mortality worldwide, yet many of these deaths are preventable. Standard care can be hindered by delays... Read more

Immunology

view channel
Image: The tool enables scientists to track real-time fluctuations in T cell function with unprecedented speed and precision (Photo courtesy of Shutterstock)

Luminescent Probe Measures Immune Cell Activity in Real Time

The human immune system plays a vital role in defending against disease, but its activity must be precisely monitored to ensure effective treatment in cancer therapy, autoimmune disorders, and organ transplants.... Read more

Industry

view channel
Image: The collaboration supports clinical validation and regulatory submissions of the new T1D 4-plex assay on Revvity’s GSP instrument (Photo courtesy of Revvity)

Revvity and Sanofi Collaborate on Program to Revolutionize Early Detection of Type 1 Diabetes

Type 1 diabetes (T1D) is a lifelong autoimmune condition in which the immune system destroys the pancreas’s insulin-producing beta cells, leading to dependence on insulin therapy. Early detection is critical... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.